Contents

Search

ombitasvir/paritaprevir/ritonavir (Viekira, Technivie)

Indications: - hepatitis C infection genotype 1 (AbbVie, Viekira) - for use in combination with dasabuvir (Viekira Pack) - hepatitis C infection genotype 4 without cirrhosis ((Technivie) - for use in combination with ribavirin Contraindications: - concurrent use of ethinyl estradiol - moderate to severe hepatic impairment (Child-Pugh class B & C) Adverse effects: - fatigue - asthenia - nausea, - insomnia - pruritus & other skin reactions - hepatoxicity [3] - elevated serum transaminases (5-fold elevation in 1%) - reactivation of hepatitis B in patients with current or previous hepatitis B infection [5] - 24% of patients with chronic hepatitis B [6] - 1.4% with resolved hepatitis B infection [6] Drug interactions: - contraceptives containing ethinyl estradiol increase likelihood of increased serum transaminases - proton pump inibitors have no effect on efficacy [4] Notes: - manufacturer: Abbvie

Interactions

drug interactions

Related

dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)

General

antiviral combination

References

  1. Brooks M FDA Clears Two New Oral Drugs for Hepatitis C. Medscape Oncology. July 24, 2015 http://www.medscape.com/viewarticle/848650
  2. FDA News Release. July 24, 2015. FDA approves Technivie for treatment of chronic hepatitis C genotype 4. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm
  3. Brown T Viekira Pak, Technivie May Up Serious Liver Injury Risk: FDA. Medscape Oncology. Oct 22, 2015 http://www.medscape.com/viewarticle/853126 - FDA Safety Alert. 10/22/2015 Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm
  4. Shiffman ML et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin in HCV-infected patients taking concomitant acid-reducing agents. Am J Gastroenterol 2016 Apr 5 PMID: 27045929
  5. FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
  6. Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 PMID: 29371017 http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext

Components

ombitasvir paritaprevir ritonavir (Norvir, RTV)